{"id":21789,"date":"2022-08-05T09:56:03","date_gmt":"2022-08-05T07:56:03","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=21789"},"modified":"2022-08-15T09:22:54","modified_gmt":"2022-08-15T07:22:54","slug":"evaxion-biotech-strengthens-its-management-with-new-ceo","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/","title":{"rendered":"Evaxion Biotech strengthens its management with new CEO"},"content":{"rendered":"\n<p><strong>Evaxion Biotech&#8217;s CEO for the past nine years, Lars Staal Wegner, will be replaced by the highly experienced Per Norl\u00e9n, who will continue the company&#8217;s rapid development with phase IIb studies, partnership with Merck and expansion of the pipeline with more cancer indications and other diseases.<\/strong><\/p>\n\n\n\n<p>Per Norl\u00e9n is currently CEO of Targinta AB and CMO of the parent company Xintela, listed on First North in Sweden [XINT], and will take over the role of CEO of Evaxion Biotech within the next six months. Per Norl\u00e9n has previously been CMO and CEO for over 10 years at Alligator Bioscience AB, listed on Nasdaq Stockholm (Main Market) [ATORX]. Prior to this, Per Norl\u00e9n was with AstraZeneca R&amp;D. Thus, an experienced person has been chosen to lead Evaxion Biotech forward.<\/p>\n\n\n\n<p class=\"has-text-align-center\"><strong>Evaxion Biotech share price YTD (USD)<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-image size-full\"><img fetchpriority=\"high\" decoding=\"async\" width=\"754\" height=\"449\" src=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/image-5.png\" alt=\"\" class=\"wp-image-21771\" srcset=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/image-5.png 754w, https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/image-5-300x179.png 300w\" sizes=\"(max-width: 754px) 100vw, 754px\" \/><\/figure>\n\n\n\n<p>Evaxion Biotech is a Danish biotech company listed in the US that uses AI-based platforms to develop immunotherapies for the treatment of cancer (the PIONEER platform) and infectious diseases, including bacterial (the EDEN platform) and viral (the RAVEN platform). Promising data from the two ongoing clinical programmes EVX-01 (treatment of metastatic melanoma) and EVX-02 (treatment of adjuvant melanoma) will, in our view, pave the way for further catalysts in the near term. We see several benefits from the use of AI-based platforms, which we believe could expand the use of immunotherapies into additional disease areas that we believe will add further value. <a href=\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech\/\">Read more here&#8230;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Evaxion Biotech&#8217;s CEO for the past nine years, Lars Staal Wegner, will be replaced by the highly experienced Per Norl\u00e9n, who will continue the company&#8217;s rapid development with phase IIb studies, partnership with Merck and expansion of the pipeline with more cancer indications and other diseases. Per Norl\u00e9n is currently CEO of Targinta AB and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":21790,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[151,165],"tags":[],"class_list":["post-21789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-cases","category-investment-cases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evaxion Biotech strengthens its management with new CEO | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaxion Biotech strengthens its management with new CEO | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"Evaxion Biotech&#8217;s CEO for the past nine years, Lars Staal Wegner, will be replaced by the highly experienced Per Norl\u00e9n, who will continue the company&#8217;s rapid development with phase IIb studies, partnership with Merck and expansion of the pipeline with more cancer indications and other diseases. Per Norl\u00e9n is currently CEO of Targinta AB and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2022-08-05T07:56:03+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-08-15T07:22:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"533\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Kapital Partner\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Kapital Partner\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/\"},\"author\":{\"name\":\"Kapital Partner\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe\"},\"headline\":\"Evaxion Biotech strengthens its management with new CEO\",\"datePublished\":\"2022-08-05T07:56:03+00:00\",\"dateModified\":\"2022-08-15T07:22:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/\"},\"wordCount\":254,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg\",\"articleSection\":[\"Company cases\",\"Investment cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/\",\"name\":\"Evaxion Biotech strengthens its management with new CEO | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg\",\"datePublished\":\"2022-08-05T07:56:03+00:00\",\"dateModified\":\"2022-08-15T07:22:54+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg\",\"width\":800,\"height\":533},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Investment cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Evaxion Biotech strengthens its management with new CEO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe\",\"name\":\"Kapital Partner\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g\",\"caption\":\"Kapital Partner\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaxion Biotech strengthens its management with new CEO | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/","og_locale":"en_US","og_type":"article","og_title":"Evaxion Biotech strengthens its management with new CEO | Kapital Partner A\/S","og_description":"Evaxion Biotech&#8217;s CEO for the past nine years, Lars Staal Wegner, will be replaced by the highly experienced Per Norl\u00e9n, who will continue the company&#8217;s rapid development with phase IIb studies, partnership with Merck and expansion of the pipeline with more cancer indications and other diseases. Per Norl\u00e9n is currently CEO of Targinta AB and [&hellip;]","og_url":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2022-08-05T07:56:03+00:00","article_modified_time":"2022-08-15T07:22:54+00:00","og_image":[{"width":800,"height":533,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg","type":"image\/jpeg"}],"author":"Kapital Partner","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Kapital Partner","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/"},"author":{"name":"Kapital Partner","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe"},"headline":"Evaxion Biotech strengthens its management with new CEO","datePublished":"2022-08-05T07:56:03+00:00","dateModified":"2022-08-15T07:22:54+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/"},"wordCount":254,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg","articleSection":["Company cases","Investment cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/","url":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/","name":"Evaxion Biotech strengthens its management with new CEO | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg","datePublished":"2022-08-05T07:56:03+00:00","dateModified":"2022-08-15T07:22:54+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2022\/08\/evaxion-b.jpg","width":800,"height":533},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/evaxion-biotech-strengthens-its-management-with-new-ceo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"Investment cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/"},{"@type":"ListItem","position":3,"name":"Evaxion Biotech strengthens its management with new CEO"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/f79e57d92a60bb503a02eff0aadbe1fe","name":"Kapital Partner","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0ac4318887c096ae923f37487d5e98fd?s=96&d=mm&r=g","caption":"Kapital Partner"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/21789"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=21789"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/21789\/revisions"}],"predecessor-version":[{"id":21793,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/21789\/revisions\/21793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/21790"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=21789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=21789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=21789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}